Kenneth Nielson, MD
Cardiovascular Disease · Salt Lake City, UTNPI 1063404929
Payments from drug & device makers
Across 476 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Amgen$1K
- Novartis$843
- E.r. Squibb & Sons, L.L.C.$837
- Johnson & Johnson$822
- Pfizer$667
- plus $3K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 40 | $1,882 |
| Amgen | 52 | $1,024 |
| Novartis | 50 | $843 |
| E.r. Squibb & Sons, L.L.C. | 70 | $837 |
| Johnson & Johnson | 48 | $822 |
| Pfizer | 47 | $667 |
| Boehringer Ingelheim | 30 | $538 |
| Merck | 22 | $363 |
| Philips North America LLC | 15 | $328 |
| Chiesi USA, Inc. | 11 | $211 |
| AstraZeneca | 15 | $180 |
| Amarin Pharma, Inc. | 11 | $173 |
| Bayer | 9 | $154 |
| Actelion Pharmaceuticals US, Inc. | 9 | $138 |
| Heartflow, Inc. | 4 | $124 |
| Abbott | 4 | $110 |
| Gilead | 6 | $109 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $96 |
| Daiichi Sankyo Inc. | 5 | $78 |
| Lexicon Pharmaceuticals, Inc. | 3 | $61 |
| Regeneron Healthcare Solutions, Inc. | 3 | $51 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $48 |
| Lantheus Medical Imaging, Inc. | 2 | $44 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $42 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Alnylam Pharmaceuticals Inc. | 1 | $34 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Atricure, Inc. | 1 | $26 |
| Impulse Dynamics (USA) Inc. | 1 | $24 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Biotronik Inc. | 1 | $16 |
| Medtronic | 1 | $15 |
| Sanofi | 1 | $15 |
How this compares
$9,135 in reported general payments places this provider in the 70th percentile of 131 cardiovascular disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Salt Lake City
- John RyanSalt Lake City$4.2M
- Jeffrey AndersonSalt Lake City$1.7M
- Robert FowlesSalt Lake City$611K
- Benjamin PetersonSalt Lake City$179K
- James FangSalt Lake City$161K
- Edward GilbertSalt Lake City$99K
- Lowell ChangSalt Lake City$96K
- Jeffrey OsbornSalt Lake City$92K
- Hannah RaaschSalt Lake City$62K
- Richard MeredithSalt Lake City$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.